Stock A069620 DAEWOONG PHARMACEUTICAL CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Daewoong Pharmaceutical Co., Ltd

Equities

A069620

KR7069620003

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 14/05/2024 am IST 		5-day change 1st Jan Change
1,11,500 KRW +1.64% Intraday chart for Daewoong Pharmaceutical Co., Ltd -0.80% -4.54%
24/04 Korean Sugar Imports Plunge 14% as Diabetes Cases Surge MT
12/04 AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 14,19,120 17,75,845 16,38,243 17,54,469 13,43,932 12,82,949 - -
Enterprise Value (EV) 2 1,783 2,155 2,037 1,754 1,344 1,614 1,605 1,682
P/E ratio 70.2 x 561 x 45.5 x 36.1 x 12 x 16.3 x 11.4 x 9.98 x
Yield 0.44% 0.36% 0.41% - - 0.54% 0.54% 0.94%
Capitalization / Revenue 1.41 x 1.88 x 1.55 x 1.51 x 1.1 x 1 x 0.92 x 0.86 x
EV / Revenue 1.77 x 2.28 x 1.93 x 1.51 x 1.1 x 1.25 x 1.16 x 1.12 x
EV / EBITDA 28.6 x 47.2 x 15.9 x 12.7 x 7.95 x 8.82 x 7.79 x 7.16 x
EV / FCF 94.4 x 27.9 x 73.4 x - - 16.5 x 12.5 x 13.8 x
FCF Yield 1.06% 3.59% 1.36% - - 6.07% 8.02% 7.25%
Price to Book 2.57 x 3.08 x 2.79 x - - 1.48 x 1.4 x 1.19 x
Nbr of stocks (in thousands) 10,321 10,763 11,069 11,069 11,506 11,506 - -
Reference price 3 1,37,500 1,65,000 1,48,000 1,58,500 1,16,800 1,11,500 1,11,500 1,11,500
Announcement Date 13/02/20 15/02/21 15/02/22 15/02/23 05/02/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,005 944.8 1,055 1,161 1,222 1,289 1,389 1,498
EBITDA 1 62.4 45.62 128.4 138 169.1 183 205.9 235
EBIT 1 31.45 12.63 95.5 106 133.4 145 165.4 194.4
Operating Margin 3.13% 1.34% 9.05% 9.12% 10.92% 11.25% 11.91% 12.98%
Earnings before Tax (EBT) 1 16.41 -7.785 31.72 85.74 111.6 103 140.2 165.2
Net income 1 20.23 3.139 40.48 80.14 111.5 79.34 113 128.5
Net margin 2.01% 0.33% 3.84% 6.9% 9.12% 6.16% 8.14% 8.58%
EPS 2 1,960 294.0 3,253 4,387 9,760 6,856 9,790 11,171
Free Cash Flow 3 18,884 77,281 27,763 - - 98,000 1,28,667 1,22,000
FCF margin 1,878.63% 8,180.05% 2,631.18% - - 7,603.09% 9,263.64% 8,144.19%
FCF Conversion (EBITDA) 30,260.08% 1,69,393.08% 21,618.49% - - 53,566.55% 62,481.21% 51,914.89%
FCF Conversion (Net income) 93,353.69% 24,62,165.05% 68,580.57% - - 1,23,519.03% 1,13,830.73% 94,941.63%
Dividend per Share 2 600.0 600.0 600.0 - - 600.0 600.0 1,050
Announcement Date 13/02/20 15/02/21 15/02/22 15/02/23 05/02/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 265.1 275.3 272.2 293.8 301.5 293.8 292.3 307.1 303 319.6 296.6 331.5 333.1 355.3 335.1
EBITDA 1 - - - 41.44 38.25 23.45 39.25 45.02 43.17 41.63 42.75 46.25 46.65 46.8 -
EBIT 1 23.92 24.71 26.77 33.57 30.31 15.3 30.97 36.19 34.2 32.04 31.23 40.6 38.5 37.4 35.3
Operating Margin 9.02% 8.97% 9.84% 11.43% 10.05% 5.21% 10.6% 11.79% 11.29% 10.03% 10.53% 12.25% 11.56% 10.53% 10.53%
Earnings before Tax (EBT) 1 20.27 20.26 24.17 27.71 28.96 4.897 27.16 31.99 26.11 26.42 13.94 35.5 33.4 32.3 30.2
Net income 1 14.48 34.85 17.52 20.74 21.51 20.38 20.47 28.76 19.76 42.5 10.83 27 25.4 24.5 22.9
Net margin 5.46% 12.66% 6.44% 7.06% 7.13% 6.93% 7% 9.37% 6.52% 13.3% 3.65% 8.14% 7.63% 6.9% 6.83%
EPS - - - - - - 1,832 - - - - - - - -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 27/10/21 15/02/22 28/04/22 28/07/22 31/10/22 15/02/23 03/05/23 27/07/23 27/10/23 05/02/24 29/04/24 - - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 364 379 399 - - 331 322 399
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 5.829 x 8.317 x 3.106 x - - 1.812 x 1.562 x 1.698 x
Free Cash Flow 2 18,884 77,281 27,763 - - 98,000 1,28,667 1,22,000
ROE (net income / shareholders' equity) 3.71% 0.56% 6.01% - - 9.4% 12.6% 12.5%
ROA (Net income/ Total Assets) 1.86% 0.27% 2.93% - - 5.57% 6.94% 7.1%
Assets 1 1,088 1,143 1,383 - - 1,425 1,628 1,810
Book Value Per Share 3 53,580 53,521 53,015 - - 75,555 79,542 93,890
Cash Flow per Share 3 3,681 9,225 4,357 - - 12,002 14,193 14,083
Capex 1 19.1 21.1 20.2 - - 61.3 46 66.5
Capex / Sales 1.9% 2.23% 1.91% - - 4.76% 3.31% 4.44%
Announcement Date 13/02/20 15/02/21 15/02/22 15/02/23 05/02/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Daewoong Pharmaceutical Co., Ltd

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
DAEWOONG PHARMACEUTICAL CO., LTD Stock Daewoong Pharmaceutical Co., Ltd
-4.54% 92Cr
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+22.69% 4.38TCr
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+25.56% 2.3TCr
SANDOZ GROUP AG Stock Sandoz Group AG
+18.00% 1.53TCr
CIPLA LIMITED Stock Cipla Limited
+8.91% 1.37TCr
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+42.72% 1.2TCr
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-7.49% 697.64Cr
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 678.76Cr
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 572.55Cr
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+12.22% 559.02Cr
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A069620 Stock
  4. Financials Daewoong Pharmaceutical Co., Ltd
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW